Source:http://linkedlifedata.com/resource/pubmed/id/14749699
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2004-2-24
|
| pubmed:abstractText |
Little information is available on long-term immune reconstitution after therapy with alemtuzumab in B-CLL patients. We present long-term follow-up data for blood lymphocyte subsets analysed by flow cytometry in previously untreated B-CLL patients who received alemtuzumab subcutaneously as first-line therapy. All lymphoid subsets were significantly (P<0.001) and profoundly reduced; the median end-of-treatment counts for CD4(+), CD8(+), CD3(-)56(+) (natural killer (NK)), CD3(+)56(+) (NK-T) and CD19(+)5(-) (normal B) cells were 43, 20, 4, 1 and 8 cells/microl, respectively. The median cell count of all subsets remained at <25% of the baseline values for >9 months post-treatment. CD4(+) and CD8(+) levels in blood had reached >100 cells/microl in >50% of the patients at 4 months after the end of treatment. One patient had a cytomegalovirus reactivation and one patient developed Pneumocystis carinii pneumonia during therapy. No opportunistic or other major infections were recorded during unmaintained, long-term follow-up. There was no correlation between the cumulative dose of alemtuzumab and the severity or length of immunosuppression. CD52(-) T-cell subsets occurred during the treatment and comprised >80% of all CD4(+) and CD8(+) cells in the blood at the end of therapy. These subpopulations declined gradually during unmaintained follow-up. The relationship between these observations and the safety/antitumour effects of alemtuzumab is discussed.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
484-90
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:14749699-Adult,
pubmed-meshheading:14749699-Aged,
pubmed-meshheading:14749699-Antibodies, Monoclonal,
pubmed-meshheading:14749699-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:14749699-Antibodies, Neoplasm,
pubmed-meshheading:14749699-Antigens, CD,
pubmed-meshheading:14749699-Antineoplastic Agents,
pubmed-meshheading:14749699-Case-Control Studies,
pubmed-meshheading:14749699-Follow-Up Studies,
pubmed-meshheading:14749699-Humans,
pubmed-meshheading:14749699-Immunity, Cellular,
pubmed-meshheading:14749699-Immunophenotyping,
pubmed-meshheading:14749699-Injections, Subcutaneous,
pubmed-meshheading:14749699-Killer Cells, Natural,
pubmed-meshheading:14749699-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:14749699-Middle Aged,
pubmed-meshheading:14749699-Remission Induction,
pubmed-meshheading:14749699-T-Lymphocytes,
pubmed-meshheading:14749699-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
|
| pubmed:affiliation |
1Department of Haematology, Karolinska Hospital, Stockholm, Sweden.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|